LGND - Scalable Platform Business And Strong Pipeline Position Ligand For Long-Term Growth

• Unlike traditional biotech companies, Ligand’s business model revolves around helping biotech companies to discover and develop medicines.
• Scalable platform technologies such as Captisol, OmniAb, Ion Channel Technologies and Pelican Expression and a strong pipeline of partners provide multiple pathways to growth.
• Management has demonstrated good capital allocation skills and successfully executed on the M&A strategies on Captisol and OmniAb.
• Company is fairly valued and upcoming catalysts in 2021 could result in earnings growth and P/E re-rating.

For further details see: